Platelet aggregation machinery

The platelet aggregation machinery encompasses the integrated system of cell surface receptors, intracellular signaling molecules, and adhesion proteins that facilitate the transition of platelets from a quiescent state to an activated, aggregate-forming state (StatPearls, NBK545155). This machinery is vital for physiological hemostasis, preventing excessive blood loss following vascular injury by forming a primary platelet plug (NIH, National Heart, Lung, and Blood Institute). However, pathological overactivation of this system is a central driver of arterial thrombosis, which can lead to life-threatening events such as myocardial infarction and ischemic stroke (PubMed, PMID: 28838937). Therapeutic intervention typically involves antiplatelet drugs that target specific nodes within this machinery, such as the P2Y12 receptor or the GP IIb/IIIa complex, to reduce the risk of clot formation (StatPearls, NBK470418). While highly effective in preventing cardiovascular events, these therapies must be carefully managed due to the inherent risk of bleeding complications associated with impaired platelet function (PubMed, PMID: 30571494).

Other names

Platelet activation pathwayHemostatic machineryThrombotic cascadePlatelet aggregation systemPlatelet aggregation

Inhibition of platelet aggregation through various pathways, including irreversible inhibition of cyclooxygenase-1 (COX-1) (PubChem, CID 2244), antagonism of the P2Y12 adenosine diphosphate (ADP) receptor (UniProt, Q9H244), blockade of the glycoprotein IIb/IIIa (integrin alpha-IIb/beta-3) receptor (UniProt, P08514), and antagonism of the protease-activated receptor-1 (PAR-1) (PubMed, PMID: 22205677).